Studies of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity among patients with acute leukemia in complete remission

Moshe Talpaz, Marc Bielski, Evan M Hersh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Low natural killer (NK) cell activity against the K-562 leukemia cell line was observed in patients with acute leukemia in the early stages of remission, i.e., 2-4 months (11.3%±7.95% specific target cell lysis). This parameter was found to be normal among leukemia patients after a longer time in remission (19.53%±7.55%) when compared with healthy donors (18.46%±12.98%). A similar pattern of activity was observed in studies of antibody-dependent cell-mediated cytolysis (ADCC) to the CEM lymphoid tumor cell line in the same group (37.58%±12.4% vs. 51%±6.79% specific target cell lysis). ADCC to chicken red blood cells (CRBC) and to human red blood cells (HRBC) was not significantly different from that for healthy controls at either duration of remission. Nine patients relapsed over a follow-up period of 9 months. They were found to have slightly lower NK activity (14.4%±9.3%) and ADCC to CEM (41.4%±8.5%) than the patients who remained in remission (17.1%±6.8%; 48.7%±9.7%, respectively). These data indicate a lymphocyte deficit which may persist for some time after remission has been induced, and which may be due to the effect of leukemic cell burden or the effect of aggressive chemotherapy.

Original languageEnglish (US)
Pages (from-to)96-98
Number of pages3
JournalCancer Immunology, Immunotherapy
Volume14
Issue number2
DOIs
StatePublished - Dec 1982
Externally publishedYes

Fingerprint

Antibody-Dependent Cell Cytotoxicity
Natural Killer Cells
Leukemia
Antibodies
Erythrocytes
Lymphocytes
Tumor Cell Line
Chickens
Tissue Donors
Drug Therapy
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

@article{e82d483bf7d2439681c353aae62b5ef0,
title = "Studies of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity among patients with acute leukemia in complete remission",
abstract = "Low natural killer (NK) cell activity against the K-562 leukemia cell line was observed in patients with acute leukemia in the early stages of remission, i.e., 2-4 months (11.3{\%}±7.95{\%} specific target cell lysis). This parameter was found to be normal among leukemia patients after a longer time in remission (19.53{\%}±7.55{\%}) when compared with healthy donors (18.46{\%}±12.98{\%}). A similar pattern of activity was observed in studies of antibody-dependent cell-mediated cytolysis (ADCC) to the CEM lymphoid tumor cell line in the same group (37.58{\%}±12.4{\%} vs. 51{\%}±6.79{\%} specific target cell lysis). ADCC to chicken red blood cells (CRBC) and to human red blood cells (HRBC) was not significantly different from that for healthy controls at either duration of remission. Nine patients relapsed over a follow-up period of 9 months. They were found to have slightly lower NK activity (14.4{\%}±9.3{\%}) and ADCC to CEM (41.4{\%}±8.5{\%}) than the patients who remained in remission (17.1{\%}±6.8{\%}; 48.7{\%}±9.7{\%}, respectively). These data indicate a lymphocyte deficit which may persist for some time after remission has been induced, and which may be due to the effect of leukemic cell burden or the effect of aggressive chemotherapy.",
author = "Moshe Talpaz and Marc Bielski and Hersh, {Evan M}",
year = "1982",
month = "12",
doi = "10.1007/BF00200175",
language = "English (US)",
volume = "14",
pages = "96--98",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Studies of natural killer cell activity and antibody-dependent cell-mediated cytotoxicity among patients with acute leukemia in complete remission

AU - Talpaz, Moshe

AU - Bielski, Marc

AU - Hersh, Evan M

PY - 1982/12

Y1 - 1982/12

N2 - Low natural killer (NK) cell activity against the K-562 leukemia cell line was observed in patients with acute leukemia in the early stages of remission, i.e., 2-4 months (11.3%±7.95% specific target cell lysis). This parameter was found to be normal among leukemia patients after a longer time in remission (19.53%±7.55%) when compared with healthy donors (18.46%±12.98%). A similar pattern of activity was observed in studies of antibody-dependent cell-mediated cytolysis (ADCC) to the CEM lymphoid tumor cell line in the same group (37.58%±12.4% vs. 51%±6.79% specific target cell lysis). ADCC to chicken red blood cells (CRBC) and to human red blood cells (HRBC) was not significantly different from that for healthy controls at either duration of remission. Nine patients relapsed over a follow-up period of 9 months. They were found to have slightly lower NK activity (14.4%±9.3%) and ADCC to CEM (41.4%±8.5%) than the patients who remained in remission (17.1%±6.8%; 48.7%±9.7%, respectively). These data indicate a lymphocyte deficit which may persist for some time after remission has been induced, and which may be due to the effect of leukemic cell burden or the effect of aggressive chemotherapy.

AB - Low natural killer (NK) cell activity against the K-562 leukemia cell line was observed in patients with acute leukemia in the early stages of remission, i.e., 2-4 months (11.3%±7.95% specific target cell lysis). This parameter was found to be normal among leukemia patients after a longer time in remission (19.53%±7.55%) when compared with healthy donors (18.46%±12.98%). A similar pattern of activity was observed in studies of antibody-dependent cell-mediated cytolysis (ADCC) to the CEM lymphoid tumor cell line in the same group (37.58%±12.4% vs. 51%±6.79% specific target cell lysis). ADCC to chicken red blood cells (CRBC) and to human red blood cells (HRBC) was not significantly different from that for healthy controls at either duration of remission. Nine patients relapsed over a follow-up period of 9 months. They were found to have slightly lower NK activity (14.4%±9.3%) and ADCC to CEM (41.4%±8.5%) than the patients who remained in remission (17.1%±6.8%; 48.7%±9.7%, respectively). These data indicate a lymphocyte deficit which may persist for some time after remission has been induced, and which may be due to the effect of leukemic cell burden or the effect of aggressive chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0020413553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020413553&partnerID=8YFLogxK

U2 - 10.1007/BF00200175

DO - 10.1007/BF00200175

M3 - Article

C2 - 6965233

AN - SCOPUS:0020413553

VL - 14

SP - 96

EP - 98

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -